How are pediatric B cell ? derived large cell lymphomas (LCLs) treated?

Updated: Jun 14, 2018
  • Author: J Martin Johnston, MD; Chief Editor: Max J Coppes, MD, PhD, MBA  more...
  • Print

Patients with B cell ̶ derived large cell lymphomas (LCLs) are treated effectively using regimens for SNCCL. [70, 71, 72] Outcomes are similar between the groups.

An alternative therapy is the APO regimen, consisting of doxorubicin (Adriamycin), prednisone, and vincristine [Oncovin]. [73] Methotrexate and 6-mercaptopurine have been added to this regimen.

A randomized study of children with LCLs (including B-cell LCLs) showed no advantage when cyclophosphamide was added to the APO regimen. [74] Therefore, this therapy has the advantage of avoiding exposure to an alkylating agent. However, the cumulative dose of doxorubicin is 450 mg/m2.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!